07:00 , Oct 7, 2013 |  BioCentury  |  Product Development

Differentiated DNA repair

When Teva Pharmaceutical Industries Ltd. refocused R&D on key growth drivers last December, management said cancer programs would have to clear a high hurdle to justify investment. Research programs from Cancer Research Technology Ltd. targeting...
07:00 , Apr 4, 2011 |  BioCentury  |  Strategy

Half-A-Loaf Dilemma

Cephalon Inc. 's board is evaluating the two options in last week's hostile takeover bid from Valeant Pharmaceuticals International Inc. : take the $5.7 billion in cash for the whole company, or take $2.8 billion...